247 related articles for article (PubMed ID: 19671788)
1. The Euro-Phospholipid project: epidemiology of the antiphospholipid syndrome in Europe.
Cervera R; Boffa MC; Khamashta MA; Hughes GR
Lupus; 2009 Sep; 18(10):889-93. PubMed ID: 19671788
[TBL] [Abstract][Full Text] [Related]
2. Lessons from the "Euro-Phospholipid" project.
Cervera R
Autoimmun Rev; 2008 Jan; 7(3):174-8. PubMed ID: 18190874
[TBL] [Abstract][Full Text] [Related]
3. Antiphospholipid syndrome in Latin American patients: clinical and immunologic characteristics and comparison with European patients.
García-Carrasco M; Galarza C; Gómez-Ponce M; Cervera R; Rojas-Rodríguez J; Espinosa G; Bucciarelli S; Gómez-Puerta JA; Bové A; Escárcega RO; Font J
Lupus; 2007; 16(5):366-73. PubMed ID: 17576741
[TBL] [Abstract][Full Text] [Related]
4. High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus.
Ruiz-Irastorza G; Egurbide MV; Ugalde J; Aguirre C
Arch Intern Med; 2004 Jan; 164(1):77-82. PubMed ID: 14718326
[TBL] [Abstract][Full Text] [Related]
5. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients.
Cervera R; Serrano R; Pons-Estel GJ; Ceberio-Hualde L; Shoenfeld Y; de Ramón E; Buonaiuto V; Jacobsen S; Zeher MM; Tarr T; Tincani A; Taglietti M; Theodossiades G; Nomikou E; Galeazzi M; Bellisai F; Meroni PL; Derksen RH; de Groot PG; Baleva M; Mosca M; Bombardieri S; Houssiau F; Gris JC; Quéré I; Hachulla E; Vasconcelos C; Fernández-Nebro A; Haro M; Amoura Z; Miyara M; Tektonidou M; Espinosa G; Bertolaccini ML; Khamashta MA;
Ann Rheum Dis; 2015 Jun; 74(6):1011-8. PubMed ID: 24464962
[TBL] [Abstract][Full Text] [Related]
6. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients.
Cervera R; Piette JC; Font J; Khamashta MA; Shoenfeld Y; Camps MT; Jacobsen S; Lakos G; Tincani A; Kontopoulou-Griva I; Galeazzi M; Meroni PL; Derksen RH; de Groot PG; Gromnica-Ihle E; Baleva M; Mosca M; Bombardieri S; Houssiau F; Gris JC; Quéré I; Hachulla E; Vasconcelos C; Roch B; Fernández-Nebro A; Boffa MC; Hughes GR; Ingelmo M;
Arthritis Rheum; 2002 Apr; 46(4):1019-27. PubMed ID: 11953980
[TBL] [Abstract][Full Text] [Related]
7. Features associated with epilepsy in the antiphospholipid syndrome.
Shoenfeld Y; Lev S; Blatt I; Blank M; Font J; von Landenberg P; Lev N; Zaech J; Cervera R; Piette JC; Khamashta MA; Bertolaccini ML; Hughes GR; Youinou P; Meroni PL; Pengo V; Alves JD; Tincani A; Szegedi G; Lakos G; Sturfelt G; Jönsen A; Koike T; Sanmarco M; Ruffatti A; Ulcova-Gallova Z; Praprotnik S; Rozman B; Lorber M; Chapman J; van-Breda-Vriezman PJ; Damoiseaux J
J Rheumatol; 2004 Jul; 31(7):1344-8. PubMed ID: 15229954
[TBL] [Abstract][Full Text] [Related]
8. The association of thrombocytopenia with systemic manifestations in the antiphospholipid syndrome.
Krause I; Blank M; Fraser A; Lorber M; Stojanovich L; Rovensky J; Shoenfeld Y
Immunobiology; 2005; 210(10):749-54. PubMed ID: 16325493
[TBL] [Abstract][Full Text] [Related]
9. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients.
Cervera R; Khamashta MA; Shoenfeld Y; Camps MT; Jacobsen S; Kiss E; Zeher MM; Tincani A; Kontopoulou-Griva I; Galeazzi M; Bellisai F; Meroni PL; Derksen RH; de Groot PG; Gromnica-Ihle E; Baleva M; Mosca M; Bombardieri S; Houssiau F; Gris JC; Quéré I; Hachulla E; Vasconcelos C; Roch B; Fernández-Nebro A; Piette JC; Espinosa G; Bucciarelli S; Pisoni CN; Bertolaccini ML; Boffa MC; Hughes GR;
Ann Rheum Dis; 2009 Sep; 68(9):1428-32. PubMed ID: 18801761
[TBL] [Abstract][Full Text] [Related]
10. Asymptomatic avascular necrosis in patients with primary antiphospholipid syndrome in the absence of corticosteroid use: a prospective study by magnetic resonance imaging.
Tektonidou MG; Malagari K; Vlachoyiannopoulos PG; Kelekis DA; Moutsopoulos HM
Arthritis Rheum; 2003 Mar; 48(3):732-6. PubMed ID: 12632427
[TBL] [Abstract][Full Text] [Related]
11. Hypocomplementemia in systemic lupus erythematosus and primary antiphospholipid syndrome: prevalence and clinical significance in 667 patients.
Ramos-Casals M; Campoamor MT; Chamorro A; Salvador G; Segura S; Botero JC; Yagüe J; Cervera R; Ingelmo M; Font J
Lupus; 2004; 13(10):777-83. PubMed ID: 15540510
[TBL] [Abstract][Full Text] [Related]
12. The Ped-APS Registry: the antiphospholipid syndrome in childhood.
Avcin T; Cimaz R; Rozman B;
Lupus; 2009 Sep; 18(10):894-9. PubMed ID: 19671789
[TBL] [Abstract][Full Text] [Related]
13. The Euro-lupus project: epidemiology of systemic lupus erythematosus in Europe.
Cervera R; Khamashta MA; Hughes GR
Lupus; 2009 Sep; 18(10):869-74. PubMed ID: 19671784
[TBL] [Abstract][Full Text] [Related]
14. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus.
Danowski A; de Azevedo MN; de Souza Papi JA; Petri M
J Rheumatol; 2009 Jun; 36(6):1195-9. PubMed ID: 19447935
[TBL] [Abstract][Full Text] [Related]
15. Dermatologic manifestations of the antiphospholipid syndrome: two hundred consecutive cases.
Francès C; Niang S; Laffitte E; Pelletier Fl; Costedoat N; Piette JC
Arthritis Rheum; 2005 Jun; 52(6):1785-93. PubMed ID: 15934071
[TBL] [Abstract][Full Text] [Related]
16. New subsets of the antiphospholipid syndrome in 2006: "PRE-APS" (probable APS) and microangiopathic antiphospholipid syndromes ("MAPS").
Asherson RA
Autoimmun Rev; 2006 Dec; 6(2):76-80. PubMed ID: 17138247
[TBL] [Abstract][Full Text] [Related]
17. Antiphospholipid syndrome and recurrent thrombosis in children.
Berkun Y; Padeh S; Barash J; Uziel Y; Harel L; Mukamel M; Revel-Vilk S; Kenet G
Arthritis Rheum; 2006 Dec; 55(6):850-5. PubMed ID: 17139660
[TBL] [Abstract][Full Text] [Related]
18. Primary antiphospholipid syndrome as the forerunner of systemic lupus erythematosus.
Tarr T; Lakos G; Bhattoa HP; Szegedi G; Shoenfeld Y; Kiss E
Lupus; 2007; 16(5):324-8. PubMed ID: 17576733
[TBL] [Abstract][Full Text] [Related]
19. Systemic lupus erythematosus in Europe at the change of the millennium: lessons from the "Euro-Lupus Project".
Cervera R; Abarca-Costalago M; Abramovicz D; Allegri F; Annunziata P; Aydintug AO; Bacarelli MR; Bellisai F; Bernardino I; Biernat-Kaluza E; Blockmans D; Boki K; Bracci L; Campanella V; Camps MT; Carcassi C; Cattaneo R; Cauli A; Cervera R; Chwalinska-Sadowska H; Contu L; Cosyns JP; Danieli MG; DCruz D; Depresseux G; Direskeneli H; Domènech I; Espinosa G; Fernández-Nebro A; Ferrara GB; Font J; Frutos MA; Galeazzi M; Garcìa-Carrasco M; García Iglesias MF; García-Tobaruela A; George J; Gil A; González-Santos P; Grana M; Gül A; Haga HJ; de Haro-Liger M; Houssiau F; Hughes GR; Ingelmo M; Jedryka-Góral A; Khamashta MA; Lavilla P; Levi Y; López-Dulpa M; López-Soto A; Maldykowa H; Marcolongo R; Mathieu A; Morozzi G; Nicolopoulou N; Papasteriades C; Passiu G; Perelló I; Petera P; Petrovic R; Piette JC; Pintado V; de Pita O; Popovic R; Pucci G; Puddu P; de Ramón E; Ramos-Casals M; Rodríguez-Andreu J; Ruiz-Irastorza G; Sanchez-Lora J; Sanna G; Scorza R; Sebastiani GD; Sherer Y; Shoenfeld Y; Simpatico A; Sinico RA; Smolen J; Tincani A; Tokgöz G; Urbano-Márquez A; Vasconcelos C; Vázquez JJ; Veronesi J; Vianna J; Vivancos J;
Autoimmun Rev; 2006 Mar; 5(3):180-6. PubMed ID: 16483917
[TBL] [Abstract][Full Text] [Related]
20. [Subclinical and clinical manifestations of atherosclerosis in antiphospholipid syndrome].
Reshetniak TM; Seredavkina nV; Mach ES; Aleksandrova EN; Novikov AA; Cherkasova MV; Nasonov EL
Ter Arkh; 2008; 80(10):60-7. PubMed ID: 19105418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
